InnoCan Pharma Corporation
INNPF
$0.132
-$0.0031-2.30%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 111.22% | 176.96% | 333.85% | 331.10% | 445.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 111.22% | 176.96% | 333.85% | 331.10% | 445.13% |
| Cost of Revenue | 101.67% | 38.92% | 303.68% | 1,676.47% | 1,132.35% |
| Gross Profit | 112.31% | 201.13% | 338.03% | 289.55% | 412.45% |
| SG&A Expenses | 58.82% | 148.36% | 234.10% | 117.32% | 187.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.40% | 128.06% | 182.38% | 127.48% | 192.37% |
| Operating Income | 129.19% | 222.02% | 4.27% | 36.55% | -13.77% |
| Income Before Tax | 138.42% | 462.12% | 0.65% | 50.21% | -1,027.78% |
| Income Tax Expenses | -- | -- | -- | 21,300.00% | -- |
| Earnings from Continuing Operations | 115.54% | 341.41% | -18.40% | 31.97% | -1,027.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -187.00% | -399.19% | -645.24% | -135.14% | -3,233.33% |
| Net Income | 85.69% | 164.81% | -39.13% | 26.84% | -1,106.55% |
| EBIT | 129.19% | 222.02% | 4.27% | 36.55% | -13.77% |
| EBITDA | 130.16% | 226.93% | 4.53% | 36.53% | -13.35% |
| EPS Basic | 87.18% | 157.14% | -27.45% | 31.25% | -1,014.29% |
| Normalized Basic EPS | 90.38% | 166.67% | -25.00% | 45.16% | -1,200.00% |
| EPS Diluted | 87.18% | 147.62% | -27.45% | 31.25% | -680.00% |
| Normalized Diluted EPS | 90.38% | 166.67% | -25.00% | 45.16% | -1,200.00% |
| Average Basic Shares Outstanding | 9.04% | 11.43% | 7.61% | 6.97% | 3.68% |
| Average Diluted Shares Outstanding | 9.04% | 11.43% | 7.61% | 6.97% | 3.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
